Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ABOS
ACUMEN PHARMACEUTICALS, INC.
NASDAQ
$2.92
▲ UP 2.10% (0.06)

KEY STATISTICS

Market Cap$211.99 M
52w High$3.60
52w Low$1.21
Dividend Yield—
Frequency—
P/E-1.79
Volume318.18K
Shares Out.72.23M

COMPANY

LEADERSHIP

Daniel J. O'Connell
CHIEF EXECUTIVE
Daniel J. O'Connell

COMPENSATION 2026

Salary$646,354
Stock Awards$412,482
Incentive Plan Pay$305,725
All Other Comp.$20,668
Total$1,863,567

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 1, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
61

PRICE TARGET

Target High$7.00
Target Low$7.00
Target Median$7.00
Target Consensus$7.00

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.—
NOV
11
WED

PRICE

$2.92 ▲ UP 2.10% (+$0.06)
$2.84$2.88$2.92$2.969:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM2.92

About Acumen Pharmaceuticals, Inc.

https://acumenpharm.com ↗

Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company founded in 1996 in Charlottesville, VA, develops targeted immunotherapies like the Phase I ACU193 monoclonal antibody to treat Alzheimer's disease by targeting soluble amyloid-beta...

INDUSTRY

Biotechnology

A PRODUCT ACUMEN PHARMACEUTICALS, INC. IS KNOWN FOR

sabirnetug (ACU193)
sabirnetug (ACU193)

Sabirnetug, Acumen Pharmaceuticals' lead humanized monoclonal antibody, is in Phase 2 trials targeting toxic soluble amyloid beta oligomers for early Alzheimer's treatment.

COMPETITORS

COMPETITOR
ANVS COMPARE
BIIB COMPARE
LLY COMPARE
PRTA COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
49
LISTED HERE
9
RANKED BY POSITION SIZE
VTI
0.00% · 1.1M
IWM
0.00% · 1.0M
DFAS
0.00% · 100.0K
XRS2.DE
0.00% · 46.6K
AVSC
0.00% · 38.8K
RSSL
0.00% · 22.4K
RTYS.L
0.00% · 5.0K
URTY
0.00% · 1.9K
FSEV
0.04% · 928

INSTITUTIONAL OWNERSHIP

SHARES OWNED
58.13%
HOLDERS
101
TOP 12 OF 101 · RANKED BY POSITION SIZE
Ra Capital Management, L.P.
21.0M sh · $49.54M
Sands Capital Ventures, LLC
3.7M sh · $8.78M
Alyeska Investment Group, L.P.
2.5M sh · $5.78M
Franklin Resources Inc
2.3M sh · $3.94M
Blackrock Inc.
2.2M sh · $5.22M
Adar1 Capital Management, LLC
2.2M sh · $5.09M
Fmr LLC
2.0M sh · $3.47M
Vanguard Group Inc
1.7M sh · $3.49M
Knollwood Investment Advisory, LLC
1.6M sh · $3.84M
Ikarian Capital, LLC
1.1M sh · $2.49M
Hudson Bay Capital Management LP
968.9K sh · $2.29M
Laurion Capital Management LP
867.0K sh · $1.83M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
DIRECTOR
Porter Derrell
Sale · 13.0K shares
2026-06-17
★
DIRECTOR
Porter Derrell
Purchase · 6.5K shares
2026-06-15
★
DIRECTOR
Porter Derrell
Purchase · 13.0K shares
2026-06-17
★
DIRECTOR
Porter Derrell
Sale · 6.5K shares
2026-06-15

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
2 GRADES IN THE LAST 12 MONTHS
BTIG BUY B of A Securities BUY

SECTORS PEERS

PEERPRICE
IRD$6.02COMPARE
AGEN$6.86COMPARE
FATE$2.33COMPARE
ALEC$2.13COMPARE
SEER$1.96COMPARE
INO$1.25COMPARE
SPRO$1.14COMPARE
MCRB$5.07COMPARE